Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,702 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.
Johnson N, Li YC, Walton ZE, Cheng KA, Li D, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, Newell DR, D'Andrea AD, Curtin NJ, Wong KK, Shapiro GI. Johnson N, et al. Among authors: li d, li yc. Nat Med. 2011 Jun 26;17(7):875-82. doi: 10.1038/nm.2377. Nat Med. 2011. PMID: 21706030 Free PMC article.
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardy AJ, Wang Y, Capelletti M, Sarosiek KA, Moreau LA, Chowdhury D, Wickramanayake A, Harrell MI, Liu JF, D'Andrea AD, Miron A, Swisher EM, Shapiro GI. Johnson N, et al. Among authors: li yc. Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17041-6. doi: 10.1073/pnas.1305170110. Epub 2013 Oct 1. Proc Natl Acad Sci U S A. 2013. PMID: 24085845 Free PMC article.
Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.
Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, Sinha P, Carey CD, Borgman CL, Jimenez JP, Meyerson M, Ying W, Barsoum J, Wong KK, Shapiro GI. Shimamura T, et al. Among authors: li d, li yc. Clin Cancer Res. 2012 Sep 15;18(18):4973-85. doi: 10.1158/1078-0432.CCR-11-2967. Epub 2012 Jul 17. Clin Cancer Res. 2012. PMID: 22806877 Free PMC article.
D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation.
Juang SH, Lung CC, Hsu PC, Hsu KS, Li YC, Hong PC, Shiah HS, Kuo CC, Huang CW, Wang YC, Huang L, Chen TS, Chen SF, Fu KC, Hsu CL, Lin MJ, Chang CJ, Ashendel CL, Chan TC, Chou KM, Chang JY. Juang SH, et al. Among authors: li yc. Mol Cancer Ther. 2007 Jan;6(1):193-202. doi: 10.1158/1535-7163.MCT-06-0482. Mol Cancer Ther. 2007. PMID: 17237279
A large-scale population-based study reveals that gp42-IgG antibody is protective against Epstein-Barr virus-associated nasopharyngeal carcinoma.
Kong XW, Bu GL, Chen H, Huang YH, Liu Z, Kang YF, Li YC, Yu X, Wu BH, Li ZQ, Chen XC, Xie SH, Lin DF, Li T, Yan SM, Han RK, Huang N, Wang QY, Li Y, Zhang A, Zhong Q, Huang XM, Ye W, Ji MF, Cai YL, Cao SM, Zeng MS. Kong XW, et al. Among authors: li yc. J Clin Invest. 2024 Nov 26:e180216. doi: 10.1172/JCI180216. Online ahead of print. J Clin Invest. 2024. PMID: 39589824 Free article.
2,702 results